Skip to main content

Idelalisib

Details of the Drug
Generic Name:
Idelalisib
Pronunciation:
i-deh-luh-LIH-sib
Drug Type:
Phosphoinositide 3-kinase (PI3K) delta inhibitor
How the Drug is Given:

By mouth

Names:
Zydelig®
Idelalisib

Indications and Usage

Idelalisib is FDA approved to treat patients with

  • Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
  • Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
  • Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. 
  • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy

Side effects needing medical attention

Diarrhea, fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills, rash, neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations.

Idelalisib is being approved with a Boxed Warning alerting patients and healthcare professionals of the following fatal and serious adverse reactions: hepatotoxicity (liver damage caused by a drug), severe diarrhea or colitis, pneumonitis, and intestinal perforation.    

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.